Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab plus bortezomib and dexamethasone in previously treated multiple myeloma
NL-OMON39345Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tabalumab in multiple myeloma (MM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Progression-free survival and Safety. Started Jun 2013; status: active, not recruiting.
02
Drugs
tabalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON39345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39345.